EXOZ: Invizyne Technologies, Inc. Company Value to Net Income

Corporate emblem and logo of Invizyne Technologies (EXOZ)

eXoZymes Inc (EXOZ) is implementing automated laboratories with AI-controlled biocatalysis, which allows for the tracking of the -3.70 metric via this price chart. The business relies on the monetization of SimpleCell and B2B deals with industry behemoths. Its status as a synthetic biology innovator and focus on environmentally clean production provide eXoZymes Inc (EXOZ) with high authority within the professional scientific community.

EXOZ Invizyne: Price to Earnings Ratio in the range 08/14/2025 - 11/12/2026

Comprehensive metric breakdowns and analytics for Invizyne Technologies, Inc. (EXOZ)

- price and consensus price forecast:
Stock Price invizyne.com|EXOZ - Consensus Target
- market capitalization information:
Market Value eXoZymes Inc|EXOZ - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share eXoZymes|EXOZ - Company Net Assets|Market Cap to Book Value Multiple invizyne.com|EXOZ - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio eXoZymes Inc|EXOZ - Long-Term Debt to Capital|Current Liabilities to Capital Invizyne|EXOZ - Company Debts|Debt to Net Assets Ratio eXoZymes Inc|EXOZ - Company Long-Term Debts|Short-Term Debt eXoZymes|Immediate Liquidity Ratio invizyne.com
- business earnings and investment ratios data:
EXOZ - Company Net Income|Expected Net Profit eXoZymes Inc|EXOZ - Price to Earnings Ratio|Price to Expected Earnings Ratio Invizyne Technologies|EXOZ - Price/Earnings to Growth Multiple|Company Value to EBITDA eXoZymes Inc|EXOZ - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months eXoZymes|EXOZ - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months invizyne.com|EXOZ - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year eXoZymes Inc
Comprehensive company analysis:invizyne.com - EXOZ
Flagship merchandise of eXoZymes

eXoZymes Inc (EXOZ) is establishing itself as a leading visionary in cell-free synthesis, attracting the attention of industrial partners. The price-to-earnings ratio mathematically expresses market expectations regarding the monetization of these innovations. This coefficient measures the density of invested capital, demonstrating the balance between demand and the business's actual yield. By analyzing the company's P/E fluctuations, an investor assesses the aggressiveness of pricing relative to fundamental indicators.

Key competitors

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|P/E Multiple PCRX (Pacira BioSciences, Inc.)|ARS Pharmaceuticals Inc (SPRY) - Market Cap to Earnings|TBPH: Price to Earnings Ratio|AQST (Aquestive Corp) - Price to Earnings Multiple|scpharmaceuticals.com (SCPH) - Price to Earnings Ratio|Market Cap to Earnings Tectonic Therapeutic (TECX)|Price to Earnings Ratio TNXP|SXT China - Market Cap to Net Income|Price to Earnings Ratio EPRX (Eupraxia Pharmaceuticals)|BHST - Market Cap to Earnings|Price to Earnings Ratio Oramed Pharmaceuticals Inc. ORMP|ENTX - Price to Earnings Ratio|MindWalk Holdings Inc. - P/E Multiple|Market Cap to Earnings ABVC BioPharma Inc.|Cumberland Pharma (CPIX) - Price to Earnings Ratio|QNTM - Business Payback Period|Price to Earnings Ratio FGEN|TELO: Company Value to Net Income|P/E Multiple RANI|Business Payback Period synergychc.com|Price to Earnings Ratio Rallybio RLYB|LEXX: Price to Earnings Multiple|Pulmatrix, Inc. - P/E Multiple|Pheton Holdings Ltd (PTHL) - Price to Earnings Ratio|APM: P/E Multiple|Market Cap to Earnings Lyra Therapeutics Inc. (LYRA)|Price to Earnings Ratio IBO|Price to Earnings Multiple TNFA (TNF Pharma)|Price to Earnings Ratio cbdMD, Inc. (YCBD)|PRFX - Market Cap to Earnings|Altamira Therapeutics Ltd. - Price to Earnings Ratio|LIPO (Lipella Pharmaceuticals Inc) - Market Cap to Net Income|OPTN - Price to Earnings Ratio|Market Cap to Net Income PIRS|PROC: P/E Multiple|petrospharma.com - Company Value to Net Income|QLI (Qilian International Holding) - P/E Multiple|P/E Multiple Acelyrin Inc.|Price to Earnings Ratio TFF Pharma (TFFP)